Jamel A. Groves

Jamel A. Groves

Auto-generated profile, based on publicly available information

Jamel A. Groves

Scientific Affairs American Red Cross Rockville Maryland USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MBMichael Paul Busch
Michael Paul Busch
SSSusan L Stramer
Susan L Stramer
MSMars Stone
Mars Stone
EYElaine A Yu
Elaine A Yu
EGEduard Grebe
Eduard Grebe
JJJefferson M Jones
Jefferson M Jones
Background: Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination, independently and combined (“hybrid immunity”), result in partial protection from subsequent infection and strong protection from severe disease. Proportions of the US population who have been infected, vaccinated, or have hybrid immunity remain unclear, posing a challenge for assessing effective pandemic mitigation strategies. Methods: In this serial cross-sectional study, nationwide blood donor specimens collected during January–December 2021 were tested for anti-spike and anti-nucleocapsid antibodies, and donor COVID-19 vaccination history of ≥1 dose was collected. Monthly seroprevalence induced from SARS-CoV-2 infection, COVID-19 vaccination, or both, were estimated. Estimates were weighted to account for demographic differences from the general population and were compared temporally and by demographic factors. Results: Overall, 1 123 855 blood samples were assayed. From January to December 2021, the weighted percentage of donations with seropositivity changed as follows: seropositivity due to vaccination without previous infection, increase from 3.5% (95% confidence interval, 3.4%–3.7%) to 64.0%, (63.5%–64.5%); seropositivity due to previous infection without vaccination, decrease from 15.6% (15.2%–16.0%) to 11.7% (11.4%–12.0%); and seropositivity due to hybrid immunity, increase from 0.7% (0.6%–0.7%) to 18.9% (18.5%–19.3%). Combined seroprevalence from infection, vaccination, or both increased from 19.8% (19.3%–20.2%) to 94.5% (93.5%–94.0%). Infection- and vaccination-induced antibody responses varied significantly by age, race-ethnicity, and region, but not by sex. Conclusions: Our results indicate substantial increases in population humoral immunity from SARS-CoV-2 infection, COVID-19 vaccination, and hybrid immunity during 2021. These findings are important to consider in future COVID-19 studies and long-term pandemic mitigation efforts.

2 October 2024 in Transfusion
Verified
Journal Article
Open access
MFMichael Xiangchen Fu
Michael Xiangchen Fu
Helen M. FaddyHelen M. Faddy
Helen M. Faddy
DCDaniel Candotti
Daniel Candotti
JGJamel Groves
Jamel Groves
PSPaula Saa
Paula Saa
TWThe Virology Subgroup Of The Isbt Wp‐Ttid
The Virology Subgroup Of The Isbt Wp‐Ttid
Background: Hepatitis B core antibody (anti‐HBc) screening has been implemented in many blood establishments to help prevent transmission of hepatitis B virus (HBV), including from donors with occult HBV infection (OBI). We review HBV screening algorithms across blood establishments globally and their potential effectiveness in reducing transmission risk.Materials and Methods: A questionnaire on HBV screening and follow‐up strategies was distributed to members of the International Society of Blood Transfusion working party on transfusion‐transmitted infectious diseases. Screening data from 2022 were assimilated and analyzed.Results: A total of 30 unique responses were received from 25 countries. Sixteen respondents screened all donations for anti‐HBc, with 14 also screening all donations for HBV DNA. Anti‐HBc prevalence was 0.42% in all blood donors and 1.19% in new donors in low‐endemic countries; however, only 44% of respondents performed additional anti‐HBc testing to exclude false reactivity. 0.68% of anti‐HBc positive, HBsAg‐negative donors had detectable HBV DNA. Ten respondents did universal HBV DNA screening without anti‐HBc, whereas four respondents did not screen for either. Deferral strategies for anti‐HBc positive donors were highly variable. One transfusion‐transmission from an anti‐HBc negative donor was reported.Discussion: Anti‐HBc screening identifies donors with OBI but also results in the unnecessary deferral of a significant number of donors with resolved HBV infection and donors with false‐reactive anti‐HBc results. Whilst confirmation of anti‐HBc results could be improved to reduce donor deferral, transmission risks associated with anti‐HBc negative OBI donors must be considered. In high‐endemic areas, highly sensitive HBV DNA testing is required to identify infectious donors.

29 November 2023 in Transfusion
Verified
Journal Article
Closed access
LTLaura Tonnetti
Laura Tonnetti
JGJamel A. Groves
Jamel A. Groves
DSDeanna Self
Deanna Self
MYManisha Yadav
Manisha Yadav
BSBryan R. Spencer
Bryan R. Spencer
SSSusan L. Stramer
Susan L. Stramer

16 August 2025 in Transfusion
Verified
Journal Article
Open access
CRChristian Renaud
Christian Renaud
MFMilena Fedorova
Milena Fedorova
NSNathalie C. Simard
Nathalie C. Simard
JCJean‐François Côté
Jean‐François Côté
JLJeffrey M. Linnen
Jeffrey M. Linnen
ALAntoine Lewin
Antoine Lewin
Background: Tick‐borne diseases are on the rise in Canada, and southern Québec is considered one of the highest‐risk regions for Babesia emergence. Babesia is easily transmissible through blood transfusion and was the most common transfusion‐transmitted infection in the United States before the implementation of nucleic acid testing (NAT) in 2020. Babesia NAT is not yet implemented in Canada, and prevalence studies are necessary for risk assessment. Therefore, Héma‐Québec performed a new prevalence study in the summer of 2024. Study Design and Methods: Whole blood and platelet donors were sampled between June 1, 2024, and October 31, 2024, in four high‐risk administrative regions in southern Québec (i.e., Estrie, Montérégie, Montréal, and Mauricie‐Centre‐du‐Québec). The samples were tested at the American Red Cross with a qualitative Babesia NAT, i.e., the Procleix Babesia assay. Results: A total of 28,800 donations were collected and tested from four high‐risk administrative regions of the province of Quebec. All donations tested negative for Babesia NAT. Discussion: While public health data indicate that Babesia microti is emerging in southern Québec, to date, the risk of acquiring babesiosis through transfusion of blood products remains low. Partnership with public health authorities and clinicians remains essential to keep abreast of the emergence of such cases.


11 June 2025 in Transfusion
Verified
Journal Article
Closed access
JGJamel Groves
Jamel Groves
AAArtan Apostoli
Artan Apostoli
RDRoger Y. Dodd
Roger Y. Dodd
SSSusan L. Stramer
Susan L. Stramer